Skip to Main Content

Paper Details

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
J Neurooncol
10
2023
15 C, Brain Tumor, GBM, HIF2, HIF2-alpha, Hypoxia inducible factor 2-alpha, MGMT promoter, PT2385, Patients, acidic lesions, amine, anemia, erythropoietin, glioblastoma, hyperglycemia, hyponatremia, hypoxia, infiltrative disease, lymphopenia, patients, tumors, vascular endothelial growth factor
Author NameAffiliation
Benjamin M EllingsonUniversity of California Los Angeles
Benjamin M EllingsonUniversity of California Los Angeles
  • 1 - 2

Datasets

Release 1.2